21:28 , May 24, 2018 |  BC Extra  |  Preclinical News

miRNA-targeted circular single-stranded DNA to treat cancer

A Nankai University-based team developed a small circular single-stranded DNA molecule that inhibits cancer growth in cells and mice by sequestering microRNAs (miRNAs) that silence tumor suppressor genes. Preclinical deals in nucleic acid modalities over...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
00:33 , Apr 6, 2018 |  BC Innovations  |  Targets & Mechanisms

GI Band-Aid

A trio of...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
20:33 , Mar 30, 2017 |  BC Innovations  |  Translation in Brief

An E3 for TNBC

With the multiple myeloma drug Velcade bortezomib having put E3 ubiquitin ligases on the drug development map, scientists are now taking aim at another E3 ligase for a hard-to-treat solid tumor: triple-negative breast cancer (TNBC)....
07:00 , May 16, 2016 |  BioCentury  |  Emerging Company Profile

EMT interrupted

Oncodrone B.V. is developing a small molecule that can disrupt the epithelial-mesenchymal transition to prevent tumor cells from gaining invasive and malignant properties. The biotech plans to develop the compound for aggressive tumors such as...
07:00 , Mar 24, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: E-cadherin (CDH1; CD324) mutations as diagnostic markers of plasmacytoid bladder cancer

Biomarkers TECHNOLOGY: Gene profiling Mutations in CDH1 could help diagnose the aggressive plasmacytoid subtype of bladder cancer. Genetic sequencing identified CDH1 mutations in bladder tumor samples from 20 of 25 patients with the plasmacytoid subtype...
07:00 , Jun 22, 2015 |  BioCentury  |  Finance

Build-to-buy basket

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures doubled the number of build-to-buys in their deal to six, including the first build-to-buy that is homegrown by the VC. The newest cohort of companies includes Adrenergics Inc....
07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

Adrenergics, CadheRx Therapeutics, Calporta Therapeutics, GlaxoSmithKline cancer, cardiology, endocrine/metabolic news

Avalon Ventures and GlaxoSmithKline launched three build-to-buy companies, Adrenergics, CadheRx and Calporta, each with $3 million in series A funding and $7 million in R&D support. The companies will be housed at Avalon’s COI Pharmaceuticals...
02:10 , Jun 16, 2015 |  BC Extra  |  Financial News

Avalon, GSK launch three more biotechs

Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched three build-to-buy companies, each with $3 million in series A funding and $7 million in R&D support. Adrenergics Inc. is focused on therapies for dilated cardiomyopathy. CadheRx...